SUMMARY C3, factor B, and x-l-antitrypsin were determined in newborn infants with septicaemia and sclerema, associated with suspected infections, ABO or Rh incompatibility, and hyperbilirubinaemia of unknown origin, during and after treatment with exchange transfusion. Activation products from C3 and factor B, the clearance of the transfused C3, and its synthesis by the recipient were determined also. Infected newborn infants had low levels of C3 and factor B, but a normal amount of x-1-antitrypsin. Exchange transfusion lowered the level of x-l-antitrypsin and briefly corrected the low level of C3 and factor B. Activation products were formed only exceptionally. As synthesis of C3 is very active, a defective activation of complement pathway linked to an abnormal distribution in extravascular pool is postulated.
exchange transfusions in this and in other newborn infants with sepsis corrected these abnormalities. In the present study we wished to find out whether the opsonic defect was related directly to an abnormality in the synthesis of the complement component or was duLe to accelerated consuimption. Measurements of C3 phenotypes were used to study the synthesis and consumption of complement factors before and after exchange transfusion. In addition we studied the role of c-1-antitrypsin, a potential blocker of various kinins, in recovery from neonatal sepsis.
MVaterial and methods
12 premature and 5 term babies with neonatal sepsis or suspected infections were exchangetransfused with 180 ml/kg fresh (<60 hours old) citrated blood. 11 septic newborn babies, 10 Blood samples were obtained from the donors shortly before the transfusion, and from the patient at the beginning, at one-third or one-half, at two-thirds of the transfusion volume, at the end of the transfusion, and at 1, 3, 6, and 12 hours after it. Clotting was allowed to proceed at 40C and aliquots of serum were immediately frozen at -700C Samples of 0 5 ml blood were obtained from the. unbilical artery or from a heel prick.
Quantitative determinations and certain other electrophoretic studies were run on an LKB multiphor system at 40C in the room (LKB-Produkter AB S-161-25 Bromma 1. Sweden). Plates were cooled at I OC by a Haake thermostat during the run (Haake Inc., Saddle Brook, NJ 07662 USA). Current was sLipplied by an LKB 2103 power supply. Alpha-lantitrypsin concentrations were measured by radial immunodiffusion2 using a commercial specific antiserum (Atlantic Antibody Corporation, Westbrook, Maine, USA). A reference serum was provided by Behring and Co (3550 Marburg (Lahn) Germany). C3 level was determined by electroimmunodiffusion,3 using a specific antibody in 1 % agarose in 0 05 mol/l veronal and 0 009 mol/l EDTA, pH 8-6 buffer , 0 05 mol/l veronal with 0 009 mol/l calcium lactate, using a discontinuous buffer system in the buffer tank. The gel portion containing the electrophoresed serum was then cut out, transferred to another agarose plate containing antibodies to human C3 in the same buffer, and electrophoresed at 4 V/cm for 16 hours. The dried agarose plates were stained with amido-black, the peaks were then projected and drawn on paper, cut out, and the paper weighed ( Fig. 1) .
C3 phenotypes were analysed according to Pflugshaupt et al.6 Agarose gel electrophoresis at 20 V/cm for 4 hours was performed in a pH 8 6 veronal-lactate buffer, ionic strength 0 * 05 for the gel and 0 1 for the buffer tank. The agarose was then fixed in ethanol and glacial acetic acid solution, and stained with amido-black (Fig. 2) .
For further quantitation of the phenotypes, the unfixed gels were cut out and placed in an agarose gel Fig. 1 Crossed immunoelectrophoresis of native or activated C3 (Laurell technique5). For the first dimension, the starting point is on the right, anode on the left. In the second dimension, the anode is at the top. In the top portion, native C3 is defined by a single peak; in the middle portion, native C3 is completely activated by antigenantibody complexes; in the bottom portion, activated C3 by 24 hours' storage at 20°C: in the middlefigure where C3 is completely activated, a small peak oJ native C3 is still visible to the right of the major peak of C3,.. C3, factor B, alpha-i-antitrypsin in neonatal septicaemia with scierema 785 and C3 concentrations, which were initially low, increased greatly after transfusion. Moreover, C3 phenotypes switched from the recipient's to the donor's. might be expected, decreased to the donor plasma level (Fig. 5) .Before the transfusion, no decrease of K-1-antitrypsin was noted, so excluding a kinin inhibitor deficit in neonatal sepsis with sclerema.
Alpha-1-antitrypsin. Alpha-1-antitrypsin levels in acid citrate dextrose diluted plasma were 1P72 g/l + OP04
(1 SD) SD (about 20% lower than in undiluted plasma). After the transfusion, in all instances K-1-antitrypsin levels remained unchanged or, as n =38 M± Donors blood Factor B. The decrease in factor B levels was related to the severity of the disease. Fatal sepsis with sclerema ( Fig. 6) was associated with the lowest levels of this factor (26P3 + OP9 units). In blood group incompatibility and hyperbilirubinaemia, the initially normal level of factor B (89 ± 6 units) was generally unchanged by the transfusion. However in septic newborn babies with low factor B (62 ± 10-2 units), at least 3 exchange transfusions were required to increase the levels. Three out of 11 septic infants died despite the correction of factor B levels by transfusion (Fig. 7) .
Activated factor B (B) was detected only in the patient with pneumococcal sepsis, and it was not eliminated by transfusion. (Fig. 6) . In septic newborn infants, C3 levels increased only transiently after transfusion (to about two-thirds of the donor levels) and returned 4 hours later to the initial low value (55 7 ± 7-6 units, 12 hours after transfusion compared with 461 i± 5 8 units before) (Fig. 7) . By Phenotypes of C3. C3 phenotypes (FS, F, and S) were studied before and after 56 exchange transfusions. In 19 (34 %) transfusions there was a difference in phenotypes between donor and recipient. In all these patients the phenotype of the recipient converted to that of the donor after the transfusion (Figs 2 and 8) . The synthesis or consumption of C3 was calculated by multiplying the plus or minus change in the respective C3 phenotype plasma concentration per hour, with the total plasma volume, divided by the weight in kg (plasma volume was assumed to be 6% of body weight). As synthetised C3 is subjected to the same consumption as the transfused C3, the calculated C3 consumption was added to the calculated synthesis to obtain the actual synthesis. C3 levels and phenotypes were studied in 3 patients with Rh or ABO incompatibility over 6 periods of time, and in 3 septic newborn babies with sclerema or suspected infection over 7 periods of time after exchange transfusion. Quantitation of phenotypes showed that transfused C3 reached equilibrium 4 hours after transfusion (Fig. 8) . Our results indicate that the rate of C3 synthesis in all these infants was three times higher than in normal adults or in systemic lupus erythematosus using radiolabelled C3.8 There was no significant difference in C3 consumption between septic and nonseptic infants who had had transfusions.
Discussion
Various parts of the immune system have been shown to be poorly developed in the normal newborn infant, and these immunological deficits may be the reason for the poor prognosis of neonatal sepsis compared with septicaemia in an older infant. This has, for example, been well documented in streptococcal infection, where newborn infants of mothers lacking specific streptococcal antibodies that could be transferred to them through the placenta were more prone to such infections.9 Opsonic defects have also been reported in such newborn infants. It is unlikely that the lack of specific antibodies is the sole cause of the opsonic defect in the newborn. Several other factors have been implicated, including defects in the complement system. Previously we reported that the opsonic defect in neonatal septicaemia could be reversed in vitro by incubating the infant's granulocytes with normal adult serum.' In this study we investigated the integrity of the major and alternate complement pathways in septic and nonseptic newborn infants. We also evaluated the in vivo effects of exchange transfusions on the complement pathways. Low levels of C3 and factor B were noted in all septicaemic newborn infants with sclerema; after 3 or more transfusions, these factors were corrected and have remained stable. These findings raise the question whether the initial low level of complement components was due to decreased synthesis, or to increased consumption. Increased consumption could occur in the event of antikinin deficiency-such as oc-1-antitrypsin-but we could not demonstrate such an oc-l-antitrypsin deficit. Moreover, in adult sepsis, low levels of factor B are generally accompanied by the appearance of activated products of this factor, suggesting increased catabolism.4 11 We were unable to detect in the hypocomplementaemic septic newborn either factor B or C3 breakdown products. In addition, the complement consumption rate of donor's C3 and factor B was not increased in neonatal sepsis compared with newborn infants with ABO or Rh incompatibility (Fig. 9) . A slow rate of synthesis might therefore be responsible for the hypocomplementaemia. 14owever, calculation of C3 synthesis using the reappearance of recipients' phenotype after transfusion, suggested rather an increased rate of synthesis. In the light of these findings, the recorded low C3 levels (Fig. 6 
